Adjuvant activity of a small molecule TLR4 agonist discovered via structure-based virtual screening
8.0
来源：
Nature
关键字：
ML brain science
发布时间：
2025-09-30 07:42
摘要：
NSF-951, identified through structure-based virtual screening, is a small molecule TLR4 agonist with significant immunostimulatory properties. It enhances antigen-specific immune responses in mice without notable toxicity, making it a promising candidate for vaccine adjuvants. The study highlights its potential applications in both veterinary and human vaccines, emphasizing its cost-effectiveness and ease of synthesis compared to traditional adjuvants like MPLA.
原文：
查看原文
价值分投票
评分标准
新闻价值分采用0-10分制，综合考虑新闻的真实性、重要性、时效性、影响力等多个维度。
评分越高，表示该新闻的价值越大，越值得关注。
价值维度分析
domain_focus
1.0分+1.0分
business_impact
0.8分+0.8分
scientific_rigor
1.5分+1.5分
timeliness_innovation
1.5分+1.5分
investment_perspective
2.5分+2.5分
market_value_relevance
1.0分+1.0分
team_institution_background
0.5分+0.5分
technical_barrier_competition
1.0分+1.0分
关键证据
NSF-951 emerged as a potent TLR4 agonist, inducing strong proinflammatory cytokine responses.
The findings suggest that NSF-951 is a promising, cost-effective TLR4 agonist with strong immunostimulatory and adjuvant potential.
Further studies are warranted to assess its performance with other antigens and adjuvant combinations.
真实性检查
否
AI评分总结
NSF-951, identified through structure-based virtual screening, is a small molecule TLR4 agonist with significant immunostimulatory properties. It enhances antigen-specific immune responses in mice without notable toxicity, making it a promising candidate for vaccine adjuvants. The study highlights its potential applications in both veterinary and human vaccines, emphasizing its cost-effectiveness and ease of synthesis compared to traditional adjuvants like MPLA.